Gwendolyn Lupton
Nurse Practitioner · Mays Landing, NJNPI 1497388508
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 424 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 424 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$570
- Pfizer$516
- Boehringer Ingelheim$384
- Biohaven Pharmaceutical Holding Company Ltd.$376
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,588100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 103 | $1,382 |
| AstraZeneca | 53 | $1,065 |
| Novo Nordisk | 40 | $570 |
| Pfizer | 38 | $516 |
| Boehringer Ingelheim | 27 | $384 |
| Biohaven Pharmaceutical Holding Company Ltd. | 25 | $376 |
| Lilly USA, LLC | 17 | $289 |
| Philips North America LLC | 10 | $242 |
| Lundbeck LLC | 12 | $188 |
| Otsuka America Pharmaceutical, Inc. | 10 | $185 |
| Merck | 12 | $166 |
| Bayer | 9 | $157 |
| GSK | 10 | $150 |
| Daiichi Sankyo Inc. | 10 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $132 |
| Axsome Therapeutics, Inc. | 5 | $106 |
| Exact Sciences | 4 | $86 |
| W. L. Gore & Associates, Inc. | 5 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Phathom Pharmaceuticals, Inc. | 3 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Dexcom, Inc. | 1 | $23 |
| KCI USA, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Corcept Therapeutics | 1 | $17 |
| Novartis | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$148
- AIRSUPRA$148
- (5050) Ext Holter$141
- NURTEC ODT$120
How this compares
$6,588 in reported general payments places this provider in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $79,531 |
| FarxigaDapagliflozin Propanediol | 67 | $72,812 |
| MounjaroTirzepatide | 30 | $30,415 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $29,016 |
| XareltoRivaroxaban | 22 | $26,526 |
| JardianceEmpagliflozin | 19 | $23,818 |
| LinzessLinaclotide | 18 | $19,107 |
| EliquisApixaban | 19 | $15,427 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $8,360 |
| Icosapent Ethyl | 14 | $4,666 |
| VascepaIcosapent Ethyl | 22 | $4,114 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $3,712 |
| Rosuvastatin Calcium | 223 | $3,710 |
| Metformin Hcl | 94 | $3,204 |
| Atorvastatin Calcium | 272 | $2,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $570 | $79,53153 claims |
| AstraZenecaFarxiga | $1,065 | $72,81267 claims |
| Lilly USA, LLCMounjaro | $289 | $30,41530 claims |
| GSKTrelegy Ellipta | $150 | $29,01628 claims |
| Boehringer IngelheimJardiance | $384 | $23,81819 claims |
| AbbVieLinzess, Synthroid | $1,382 | $20,19233 claims |
| PfizerEliquis | $516 | $15,42719 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $62 | $8,36016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.
Other nurse practitioner in Mays Landing
- Nancy BonnetMorristown$407K
- Vanessa CoppolaCloster$205K
- Olufunmilayo IloriUnion$133K
- Janice BeitzHaddon Heights$75K
- Adewale AdefowojuUnion$70K
- Sophia KimEnglewood$70K
- Elizabeth FletcherCamden$62K
- Lannae EwingLinwood$39K
- Beth SavageNew Brunswick$34K
- Tina OcchiutoMorristown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.